<DOC>
	<DOC>NCT01611272</DOC>
	<brief_summary>To identify the following items through the post marketing surveillance under routine clinical practice after marketing authorization of Brilinta Tablet: the occurrence of unrevealed Serious Adverse Events (SAEs), current status of occurrence of Adverse Events (AEs), the factors that may influence safety and efficacy of the drug.</brief_summary>
	<brief_title>A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Brilinta</brief_title>
	<detailed_description>A Post Marketing Surveillance to evaluate the safety and efficacy of Brilinta</detailed_description>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Patients with Acute Coronary Syndromes Patients who are taking ticagrelor and ASA daily(75150mg), or Patients who are taking ticagrelor only(In the case that the patients have contraindication with ASA. Contraindication should be recorded in accordance with local PI on CRFs) Patients who have signed the Data release consent form prior to enrollment in this surveillance Patients with hypersensitivity to ingredients of this drug or with moderate or severe hepatic impairment or with medical history of intracranial hemorrhage Patients with pathological hemorrhage at the time of administration Patients being administrated strong CYP3A4 inhibitors</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Unstable angina</keyword>
</DOC>